Style is likely to Trump Facts In 2nd Debate
The second presidential debate, Romney-Obama body language, nonverbal, and demeanor signs are likely to be most effective among voters. The 2nd town-hall style, Romney-Obama is likely to trump facts in their debate.
Joe Biden, Vice President mis characterized the draw down of Afghanistan’s crowds, while Barack Obama misstated the increasing rate of health care prices, and challenger Romney exaggerated the number of unemployed Americans and his running mate, candidate for Vice President Paul D Ryan repeated the same old figures.
None of those confusing speeches in the last 2 debates looked as important, as the way they conveyed was in a very good tone, by an energetic Joe Biden, ruffled Paul Ryan, authoritative Mitt Romney, and slumberous Barack Obama.
When Romney and Obama meet on NY’s Long Is landon Tuesday night for their second debate, hosts of experts will be prepared to jump on their every speech, calling out overstatement and naming obvious exclusions. Both contenders standing in front of each other few feet apart will place set to fact-check one another as they see fit. But the voter, who is yet undecided would be more focused to candidate’s demeanor and body language than the sophisticated bullet-point policy proposals. They attune more on how they share a non verbal signs being in the same stage for one of the few times in an hour long debate.
It’s not the issues that don’t matter at all; a serious mistake, like President Gerald Ford’s misspeak during his campaign in 1976 about the Soviet sway over Europe, could harm a contender by lifting doubts about his mastery of the issue as well as his overall performance. Floyd Ciruli, researcher in Colorado said that the five-point agenda what would be mentioned at the first few minutes would be sufficient for few people while many need the complete detail. Most voters, who’re less than plan wonks and single-issue voters are looked for the gut-level reaction. UC San Diego political scientist, Samuel Popkin said that people are appointing a leader, not a scientific expert and he should be trustworthy and able to think of voters when it matters.
For many people, especially partisan’s debate simply supports defined notions. They want some candidate whose mind is firmly made up and that’s why many voters felt that Joe Biden’s energetic debate performance was more appealing than Ryan. The first presidential debate, declared Romney the winner as Obama didn’t look that confident and energetic as Romney.
Special News: National Bank of Greece (ADR)(NYSE:NBG), Seadrill Ltd(NYSE:SDRL), Teck Resources Ltd (USA) (NYSE:TCK)
Lakeway, NY — (MARKET NEWS CALL) — 12/18/2014— thenextbigtrade.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on National Bank of Greece (ADR)(NYSE:NBG), Seadrill Ltd(NYSE:SDRL), Teck Resources Ltd (USA) (NYSE:TCK).
National Bank of Greece (ADR)(NYSE:NBG)’s shares gained 10.56% to $1.99. The 52 week trading range for the company is $1.76 – $5.98. The shares of the company plunged 65% in the last one year. The company is a Greece-based financial institution. It provides a range of financial services including retail and commercial banking, asset management, brokerage, investment banking, insurance and real estate at a global level. Its segments are: Retail Banking, Corporate and Investment Banking, Global Markets and Asset Management and International Banking Operations.
Should Investors Buy NBG After The Recent Development? Find Out Here
Seadrill Ltd(NYSE:SDRL) shares jumped 10.55% to $12.16. Levi & Korsinsky on Dec. 16 announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Seadrill Limited American Depository Receipts (“ADRs”) between July 10, 2014 and November 25, 2014. The complaint alleges that Seadrill issued materially false and misleading information to the investing public. In particular, the complaint alleges that the Company issued statements suggesting that the Company would maintain its dividend until at least the end of 2015, but then on November 26, 2014, the Company disclosed it would indefinitely suspend its dividend, citing Seadrill’s need to pay down its debt to strengthen its balance sheet.
Is SDRL Going To Rise or Fall After Today’s Price Action? Find Out Here
Teck Resources Ltd (USA) (NYSE:TCK)’s shares jumped 10.46% to $12.36. The company on Dec. 17 announced the first shipment of zinc and lead in concentrate from its restarted Pend Oreille Operations in northeastern Washington State to its nearby Trail Operations in British Columbia for processing.
Can Traders Buy TCK After The Solid Rally? Get Free Trend Analysis Here
“The restart of our Pend Oreille zinc mine was completed on time and under budget and allows us to grow our zinc production at a time when global supply is constrained,” said Don Lindsay, President and CEO. “We are pleased to be operating again in Washington State and helping to support jobs and economic activity in the community, region and state.”
thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.
Stocks Highlights: Synta Pharmaceuticals Corp. (NASDAQ:SNTA), StemCells Inc. (NASDAQ:STEM), Geron Corporation (NASDAQ:GERN)
StemCells Inc. (NASDAQ:STEM)’s shares declined 2.42% to $2.02. The company on July 7 announced the appointment of Alan Trounson, Ph.D. to its Board of Directors. Dr. Trounson most recently served as President of The California Institute of Regenerative Medicine (CIRM), the largest scientific funding body for stem cell research in the world. Dr. Trounson has been the recipient of over 30 awards and distinctions for his scientific work, including pioneering work in the fields of in-vitro fertilization and stem cells. As part of his academic research, Dr. Trounson pioneered a new stem cell biology approach for the treatment of a broad range of diseases and injuries, which was awarded the first ever Australian Center of Excellence in Biotechnology grant worth $110 million dollars.
Get the Inside Scoop On STEM here with this Free Report
Synta Pharmaceuticals Corp. (NASDAQ:SNTA)’s shares decreased 4.48% to $4.37. The 52 week trading range for the company is $3.70 – $7.85. The company is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical-stage of development.
You won’t believe what we found out about SNTA
Geron Corporation (NASDAQ:GERN)’s shares dropped 0.68% and closed at $2.91. The company on June 12 announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). The partial clinical hold was placed in March 2014 due to a safety signal of hepatotoxicity that was identified in clinical trials of imetelstat. In order to resolve the partial clinical hold, the investigator, Dr. Ayalew Tefferi of Mayo Clinic, Rochester, Minnesota, was required to provide follow-up information regarding reversibility of hepatotoxicity for all patients who received imetelstat in the Myelofibrosis IST. In its letter dated June 11, 2014, the FDA informed the investigator that it had completed the review of his complete response submission and concluded that the Myelofibrosis IST may proceed.
Why Should You Buy GERN Now? Get The Free Trend Analysis Here
Hot Stocks Alert: Walter Energy, Inc. (NYSE:WLT), AK Steel Holding Corporation (NYSE:AKS), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)
Walter Energy, Inc. (NYSE:WLT)’s shares gained 0.73% to $5.55. Walter Energy’s stock price target was lowered to $3 from $5 at Goldman on June 6 and reiterates its Sell rating citing downside risk to its met coal price forecast.
WLT Move Over there Is A New Social Media Stock In Town. Read More Here
Additionally, the company on June 2 issued the following statement this morning regarding the release of EPA’s CO2 emission limits regulations for existing power plants: “Because the rules issued by EPA are aimed at controlling CO2 emissions from existing domestic power plants, we do not expect the regulation will have any material impact on Walter Energy. We primarily mine and sell metallurgical grades of coal that are used in making steel, not generating electricity. Approx. 95% of the company’s coal-related revenues come from the export of metallurgical coal.”
AK Steel Holding Corporation (NYSE:AKS)’s shares dropped 2.11% to $7.44. The company on June 11 said that it plans to release its second quarter 2014 financial results before the opening of trading on the New York Stock Exchange on July 29, 2014.
Is It The Perfect Time To Reshuffle Your Portfolio With This Multibagger? Find Out Here
Additionally, the company on June 19 provided guidance for its second quarter 2014 financial results. AK Steel said it expects to report a net loss of $0.19 to $0.23 per diluted share of common stock, which is a substantial improvement over its first quarter results. Adjusted to exclude the loss of $0.17 per diluted share for mark-to-market losses on derivatives, the company’s adjusted net loss for the second quarter would be $0.02 to $0.06 per diluted share.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares gained 0.31% to $6.57. The company announced that its Annual Meeting of Stockholders will be webcast live on June 25, 2014.
Don’t Repeat The Mistake By Not Including This Multibagger In Your Portfolio? Grab The Stock Ideas Here
Additionally, the company on June 12 announced the pricing of $200 million aggregate principal amount of its 3.625% convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”).